Lakefront Biotherapeutics NV
LKFT, GLPGF · Pharmaceutical Preparations · EDGAR filings ↗
Grade
A85gen composite 81pct→85
Notable findings
- Cash burnNegative free cash flow (-318.2M)
- Notable holderHeld by 4 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
Key metrics
Gross margin
97.3%
Operating margin
26.5%
Net margin
28.9%
Return on equity
9.9%
Return on assets
9.4%
ROIC
7.2%
Revenue growth (QoQ)
357.5%
Net-income growth
391.1%
Interest coverage
285.3×
Current ratio
20.1×
Free cash flow
-$318M
Tangible book value
$3.8B
Cash & investments
$103M
Cash runway
1q
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06652633 ↗ | Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies Hematological Malignancies | PHASE3 | Recruiting | 2039-07-01 |
| NCT04985435 ↗ | Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH) Rheumatoid Arthritis | PHASE4 | Recruiting | 2025-09-30 |
| NCT05456412 ↗ | JAK Inhibition in Ulcerative Colitis Colitis, Ulcerative | NA | Recruiting | 2025-09-01 |
| NCT05697159 ↗ | 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis Rheumatoid Arthritis, Sickness Behavior | — | Recruiting | 2025-07-31 |
| NCT06561425 ↗ | A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell | PHASE1/PHASE2 | Terminated | 2026-05-27 |
| NCT05695950 ↗ | A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis Dermatomyositis | PHASE2 | Completed | 2025-10-13 |
| NCT05856448 ↗ | A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus Systemic Lupus Erythematosus | PHASE2 | Completed | 2025-10-08 |
| NCT05502731 ↗ | Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis Rheumatoid Arthritis | PHASE4 | Unknown | 2025-03-01 |
| NCT05653791 ↗ | Early Intestinal Ultrasound in Predicting Treatment Response to Filgotinib in Ulcerative Colitis Ulcerative Colitis | — | Unknown | 2024-04-01 |
| NCT07000890 ↗ | Rheumatoid Arthritis Synovial Tissue Biopsy Study Rheumatoid Arthritis | NA | Completed | 2023-11-07 |
| NCT06043739 ↗ | Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects Bioavailability | PHASE1 | Completed | 2023-10-27 |
| NCT05479058 ↗ | A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission Ulcerative Colitis | PHASE3 | Terminated | 2023-10-09 |
| NCT02914600 ↗ | Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease Crohn's Disease | PHASE3 | Terminated | 2023-08-01 |
| NCT02065700 ↗ | Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants Rheumatoid Arthritis | PHASE2 | Completed | 2023-01-19 |
| NCT04578548 ↗ | A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Autosomal Dominant Polycystic Kidney Disease | PHASE2 | Terminated | 2022-12-14 |
| NCT02914561 ↗ | Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease Crohn's Disease | PHASE3 | Completed | 2022-11-11 |
| NCT05335447 ↗ | Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667 Healthy | PHASE1 | Completed | 2022-06-03 |
| NCT04971746 ↗ | Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects Healthy | PHASE1 | Completed | 2022-05-09 |
| NCT05272683 ↗ | Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects Healthy | PHASE1 | Completed | 2022-04-01 |
| NCT04976270 ↗ | A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects Healthy | PHASE1 | Completed | 2022-01-14 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-26 | 2025-12-31 | 0001104659-26-035163 ↗ |
| 20-F | 2025-03-27 | 2024-12-31 | 0001558370-25-003806 ↗ |
| 20-F | 2024-03-28 | 2023-12-31 | 0001558370-24-004242 ↗ |
| 20-F | 2023-03-23 | 2022-12-31 | 0001558370-23-004448 ↗ |
| 20-F | 2022-03-24 | 2021-12-31 | 0001558370-22-004270 ↗ |
| 20-F | 2021-03-25 | 2020-12-31 | 0001554855-21-000053 ↗ |
| 20-F | 2020-03-27 | 2019-12-31 | 0001558370-20-003270 ↗ |
| 20-F | 2019-03-29 | 2018-12-31 | 0001558370-19-002655 ↗ |
| 20-F | 2018-03-23 | 2017-12-31 | 0001558370-18-002364 ↗ |
| 20-F | 2017-03-23 | 2016-12-31 | 0001193125-17-093838 ↗ |
| 20-F | 2016-03-25 | 2015-12-31 | 0001193125-16-518274 ↗ |